Durbin Clinical Trial Comparator Supplies

Durbin is a specialist provider of comparator drugs for clinical trials. In addition to comparator drugs, Durbin also provides ancillary supplies and placebos. Durbin brings global sourcing expertise, transparent pricing and global custom distribution to the supply of comparators and ancillaries for clinical trials.

Durbin has over 45 years’ experience in sourcing pharmaceuticals and distributing them worldwide. Durbin combines this heritage with expertise in supplying comparators to pharmaceutical companies, both directly and via third parties, to bring a difference to the market.

Global sourcing expertise in comparator drug supply

Durbin buys direct from manufacturers and wholesalers. We have extensive and close relationships with all the top 30 pharmaceutical companies across Europe and North America. Sourcing from manufacturers and wholesalers guarantees pedigree and a reliable audit trail. We also supply placebos and ancillary items such as infusion pumps, non-PVC administration sets and infusions. We offer:

  • Any pack size
  • Single batch number
  • Any quantity
  • Same brands from multiple markets

Transparent pricing for clinical trial supply

Durbin is committed to openness throughout the supply process. We will share with you our cost price and negotiate with you a mutually acceptable profit margin. Sourcing generically can offer up to 80% discount on branded list price. Durbin works closely with all generic companies to negotiate substantial discounts for our clients. We offer:

  • Transparency in costing
  • Invoices provided for all costs
  • Negotiated profit margins
  • Partnership approach

Global bespoke distribution for clinical trial comparators

Durbin’s expertise in distribution ensures we can deliver clinical trial comparators to trial centres across the world, including China, Russia and India. We can deliver any amount and supply Europe within 24 hours. Having multi-lingual account managers enables us to negotiate directly with importation authorities to reduce duty payments and delays. The languages spoken by our team include Cantonese, Mandarin, Russian, Hindi, Spanish, French and German.

Benefits of our clinical trial comparator supply service include:

  • Frequent deliveries to over 180 countries
  • Cold chain and ambient supply chain
  • Fully tracked deliveries including temperature control
  • Specialised logistics team

Expertise in oncology, cold chain and high-value comparator drugs

Durbin has built a reputation of being able to source and supply oncology, cold chain and high-value comparator drugs quickly, efficiently and at lower than normal costs. We will devise sourcing and distribution strategies to lower the costs of clinical trial supply.

Clinical trial supply partners to the global pharmaceutical industry and specialised biotech companies

Durbin has extensive contracts and partnerships with the top 30 global pharmaceutical companies and research-based biotech companies. We can advise on all areas of clinical trial supply and logistics.

Make an enquiry

Follow this company

Follow the company to be always up to date with this company

Press Release

Durbin Donates $200,000 of Pharmaceuticals to AmeriCares

Durbin has recently donated 4,500 packs of a long-dated medicine to AmeriCares - one of the largest NGOs in the US. The medicine, worth over $200,000, has been used by AmeriCares as part of its maternal care programme. AmeriCares is a non-profit disaster relief and humanitarian aid

Address
Durbin PLC

180 Northolt Road

South Harrow

Middlesex

HA2 0LT

Other

United Kingdom

+44 20 8869 6525 +44 20 8869 6563 www.durbin.co.uk/clinical_trials.htm

Durbin Images

Products and Services

Video

White Papers

Related Projects



Alofisel (darvadstrocel) for the Treatment of Complex Perianal Fistulas in Crohn’s Disease



Alofisel® (formerly Cx601 / darvadstrocel) is the first allogeneic stem cell therapy to be approved for the treatment of complex perianal fistulas in adult patients with Crohn’s disease.

20 April 2018

Zinbryta (daclizumab) for the Treatment of Multiple Sclerosis



Zinbryta (daclizumab) is an injectable formulation jointly developed by Biogen and Abbive for the treatment of relapsing forms of multiple sclerosis (MS) in adults.

22 March 2018

Erleada (apalutamide) for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer



Erleada™ (apalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (NM-CRPC).

2 March 2018

Herzuma (trastuzumab biosimilar) for the Treatment of Breast and Gastric Cancers



Herzuma® (trastuzumab biosimilar / CT-P6) is indicated for the treatment of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer.

20 February 2018

Biktarvy for the Treatment of HIV-I



Biktarvy® is a once-daily regimen indicated for the treatment of HIV-1 infection in adults that were previously not treated with anti-retroviral medicines.

19 February 2018

Bevyxxa (betrixaban) for the Treatment of Venous Thromboembolism (VTE) in Adults



Bevyxxa (betrixaban) is a drug developed by Portola Pharmaceuticals that is indicated for the prevention and treatment of venous thromboembolism (VTE) in adults.

2 January 2018

Lartruvo (olaratumab) for the Treatment of Soft Tissue Sarcoma



Developed by Eli Lilly and Company, Lartruvo (olaratumab) in combination with doxorubicin is indicated for the treatment of soft tissue sarcoma (STS) in adult patients. The drug is available as a 10mg/ml injection.

13 September 2017

Dinutuximab beta for the Treatment of Neuroblastoma



Dinutuximab beta is an anti-GD2 monoclonal antibody indicated for the treatment of neuroblastoma in patients aged one year and above.

18 May 2017

Zejula (niraparib) for the Treatment of Ovarian Cancer



Zejula™ (Niraparib) is a poly adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitor approved for the treatment of adult patients with ovarian cancer.

9 April 2017

Translarna (ataluren) for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)



Translarna™ (ataluren) is a protein restoration therapy indicated for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The drug was developed by PTC Therapeutics.

2 April 2017

Press Release

13 September 2010

Durbin has recently donated 4,500 packs of a long-dated medicine to AmeriCares - one of the largest NGOs in the US. The medicine, worth over $200,000, has been used by AmeriCares as part of its maternal care programme. AmeriCares is a non-profit disaster relief and humanitarian aid

Read more
3 August 2010

Recent news that the number of seizures of medicines suspected of infringing intellectual property increased in 2009 to almost 11.5 million articles across the EU. This highlights the need for sponsor companies and CROs to have trusted partners within the clinical trial supply chain. Du

Read more

Regional Offices

Durbin PLC

180 Northolt Road

South Harrow

Middlesex

HA2 0LT

Other

United Kingdom

+44 20 8869 6525 +44 20 8869 6563 www.durbin.co.uk/clinical_trials.htm

Contact company

I have read and accept the terms and conditions and privacy policy.
We'd like to keep you informed about relevant promotions, products and services, if you would like not to receive these, check this box.
If you would like to hear from carefully selected third party companies, check this box
Follow this company to receive notifications when they update.